Skip to content
DraconiticResearch
Search Sources API
194,161 studies31 sourcesUpdated just now
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

1054 Pharmaceutical surgery by design: IV dosed virus ATTR02 enables in-tumor production of a universal bispecific T cell engager to address tumor heterogeneity

  • Emma Henderson1
  • Alan Parker2
  • Rahul C Khanolkar3
  • Leontine Floret3
  • Lok Hang Mak3
  • Angela Shibu3
  • James A Davies3
  • Alexander T Baker3
  • Thomas A Webb3
  • Johanne M Pentier3
  • David K Cole3
  • Andrew B Gerry3
  1. 11Accession Therapeutics, Oxford, UK
  2. 22Cardiff University, Cardiff, UK
  3. 3Accession Therapeutics, Oxford, UK
Open at sourcePDFDOICite

Related

  1. Efficacy and specific toxicity profiles of GPRC5D- versus BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: a meta-analysis of clinical trials and real-world studies
    Jiahao Ji, Xinyu Zhao, Bin Wang +2
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC
  2. 627 An innovative approach to improve bispecific T-cell engagers for solid tumor therapy
    Xiaoyun Zhu, Lijing You, Varghese George +10
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textImmunologyDOAJ
  3. Bispecific VSV-G Engagers: A Platform for Cell-Type-Specific Delivery of Viral Vectors
    G. N. Nenavath, D. Gataulin, M. Eisenstein +15
    bioRxivPreprintAll rights reservedFull textCell biologybioRxiv
  4. Case Report: CD20/BCMA bispecific CAR-T therapy for progressive multiple sclerosis
    Zhenfen Ling, Xia Liu, Wensi Li +19
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC
  5. 825 Intratumoral B7H3:CD3 bispecific T-cell engager drives localized T-cell accumulation in canine sarcoma patients
    Jason Price, James Olson, Yusuke Suita +13
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textImmunologyOncologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{henderson20261054,
  title = {{1054 Pharmaceutical surgery by design: IV dosed virus ATTR02 enables in-tumor production of a universal bispecific T cell engager to address tumor heterogeneity}},
  author = {Emma Henderson and Alan Parker and Rahul C Khanolkar and Leontine Floret and Lok Hang Mak and Angela Shibu and James A Davies and Alexander T Baker and Thomas A Webb and Johanne M Pentier and David K Cole and Andrew B Gerry},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.1054},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.1054},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 1054 Pharmaceutical surgery by design: IV dosed virus ATTR02 enables in-tumor production of a universal bispecific T cell engager to address tumor heterogeneity
AU  - Emma Henderson
AU  - Alan Parker
AU  - Rahul C Khanolkar
AU  - Leontine Floret
AU  - Lok Hang Mak
AU  - Angela Shibu
AU  - James A Davies
AU  - Alexander T Baker
AU  - Thomas A Webb
AU  - Johanne M Pentier
AU  - David K Cole
AU  - Andrew B Gerry
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.1054
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.1054
SN  - 2051-1426
ER  -